2cureX AB (publ) (2CUREX.ST)
SEK 0.4
(-5.24%)
SEK 0.4
(-5.24%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 155 Thousand SEK | 72.22% |
| 2022 | 90 Thousand SEK | -98.78% |
| 2021 | 7.39 Million SEK | -51.98% |
| 2020 | 15.39 Million SEK | 28.45% |
| 2019 | 11.98 Million SEK | 56.12% |
| 2018 | 7.67 Million SEK | 16229.79% |
| 2017 | 47 Thousand SEK | -96.51% |
| 2016 | 1.34 Million SEK | -39.72% |
| 2015 | 2.23 Million SEK | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q1 | 250 Thousand SEK | -57.77% |
| 2024 Q2 | 250 Thousand SEK | 0.0% |
| 2023 Q2 | 67 Thousand SEK | 415.38% |
| 2023 FY | 155 Thousand SEK | 72.22% |
| 2023 Q4 | 592 Thousand SEK | 580.46% |
| 2023 Q3 | 87 Thousand SEK | 29.85% |
| 2023 Q1 | 13 Thousand SEK | -84.15% |
| 2022 Q2 | 8000.00 SEK | -98.16% |
| 2022 FY | 90 Thousand SEK | -98.78% |
| 2022 Q4 | 82 Thousand SEK | 925.0% |
| 2022 Q3 | 8000.00 SEK | 0.0% |
| 2022 Q1 | 434 Thousand SEK | -82.92% |
| 2021 Q3 | 530 Thousand SEK | 13.01% |
| 2021 Q2 | 469 Thousand SEK | -87.82% |
| 2021 Q1 | 3.85 Million SEK | -26.13% |
| 2021 FY | 7.39 Million SEK | -51.98% |
| 2021 Q4 | 2.54 Million SEK | 379.43% |
| 2020 Q3 | 4.16 Million SEK | 22.3% |
| 2020 Q2 | 3.4 Million SEK | 30.93% |
| 2020 FY | 15.39 Million SEK | 28.45% |
| 2020 Q4 | 5.21 Million SEK | 25.05% |
| 2020 Q1 | 2.6 Million SEK | -45.61% |
| 2019 FY | 11.98 Million SEK | 56.12% |
| 2019 Q1 | 2.28 Million SEK | -29.46% |
| 2019 Q3 | 2.61 Million SEK | 13.57% |
| 2019 Q4 | 4.78 Million SEK | 83.3% |
| 2019 Q2 | 2.29 Million SEK | 0.52% |
| 2018 Q1 | 232 Thousand SEK | -88.63% |
| 2018 FY | 7.67 Million SEK | 16229.79% |
| 2018 Q3 | 3.39 Million SEK | 318.64% |
| 2018 Q2 | 810 Thousand SEK | 249.14% |
| 2018 Q4 | 3.24 Million SEK | -4.39% |
| 2017 Q4 | 2.04 Million SEK | 148.0% |
| 2017 FY | 47 Thousand SEK | -96.51% |
| 2017 Q1 | 341 Thousand SEK | -28.36% |
| 2017 Q2 | 698 Thousand SEK | 104.69% |
| 2017 Q3 | 823 Thousand SEK | 17.91% |
| 2016 FY | 1.34 Million SEK | -39.72% |
| 2016 Q4 | 475.97 Thousand SEK | 0.0% |
| 2015 FY | 2.23 Million SEK | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Alligator Bioscience AB (publ) | 58.1 Million SEK | 99.733% |
| Ziccum AB (publ) | 3.74 Million SEK | 95.863% |
| Modus Therapeutics Holding AB (publ) | - SEK | -Infinity% |
| BioArctic AB (publ) | 615.99 Million SEK | 99.975% |
| Sprint Bioscience AB (publ) | 50.48 Million SEK | 99.693% |
| Mendus AB (publ) | 28.48 Million SEK | 99.456% |
| Genovis AB (publ.) | 158.23 Million SEK | 99.902% |
| Intervacc AB (publ) | 8.01 Million SEK | 98.066% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 4.37 Million SEK | 96.456% |
| Active Biotech AB (publ) | - SEK | -Infinity% |
| Magle Chemoswed Holding AB (publ) | 170.44 Million SEK | 99.909% |
| Bio-Works Technologies AB (publ) | 43.89 Million SEK | 99.647% |
| Aptahem AB (publ) | 2.63 Million SEK | 94.108% |
| Vicore Pharma Holding AB (publ) | - SEK | -Infinity% |
| Kancera AB (publ) | 1.03 Million SEK | 85.024% |
| Infant Bacterial Therapeutics AB (publ) | 77 Thousand SEK | -101.299% |
| Fluicell AB (publ) | 3.33 Million SEK | 95.357% |
| Saniona AB (publ) | 16.84 Million SEK | 99.08% |
| Lipigon Pharmaceuticals AB (publ) | 16.4 Million SEK | 99.055% |
| Biovica International AB (publ) | 7.29 Million SEK | 97.874% |
| Spago Nanomedical AB (publ) | 1.2 Million SEK | 87.116% |
| AcouSort AB (publ) | 10.55 Million SEK | 98.531% |
| Xintela AB (publ) | 78 Thousand SEK | -98.718% |
| Abliva AB (publ) | 137 Thousand SEK | -13.139% |
| Egetis Therapeutics AB (publ) | 57.6 Million SEK | 99.731% |
| Karolinska Development AB (publ) | 2.01 Million SEK | 92.304% |
| OncoZenge AB (publ) | 3000.00 SEK | -5066.667% |
| Amniotics AB (publ) | - SEK | -Infinity% |
| CombiGene AB (publ) | 5.54 Million SEK | 97.204% |
| Asarina Pharma AB (publ) | - SEK | -Infinity% |
| Calliditas Therapeutics AB (publ) | 1.2 Billion SEK | 99.987% |
| Camurus AB (publ) | 1.71 Billion SEK | 99.991% |
| Corline Biomedical AB | 25.03 Million SEK | 99.381% |
| IRLAB Therapeutics AB (publ) | 5.67 Million SEK | 97.27% |
| Isofol Medical AB (publ) | 721 Thousand SEK | 78.502% |
| I-Tech AB | 120.86 Million SEK | 99.872% |
| Hansa Biopharma AB (publ) | 134.09 Million SEK | 99.884% |
| Cyxone AB (publ) | 5.14 Million SEK | 96.989% |
| ExpreS2ion Biotech Holding AB (publ) | 7.05 Million SEK | 97.801% |
| Biosergen AB | - SEK | -Infinity% |
| Cantargia AB (publ) | - SEK | -Infinity% |
| NextCell Pharma AB | 10.66 Million SEK | 98.547% |
| Xspray Pharma AB (publ) | - SEK | -Infinity% |
| Elicera Therapeutics AB (publ) | 11.23 Million SEK | 98.62% |
| Nanologica AB (publ) | 1.44 Million SEK | 89.258% |
| SynAct Pharma AB | - SEK | -Infinity% |
| Annexin Pharmaceuticals AB (publ) | - SEK | -Infinity% |
| Stayble Therapeutics AB (publ) | - SEK | -Infinity% |
| LIDDS AB (publ) | - SEK | -Infinity% |
| Lipum AB (publ) | 53 Thousand SEK | -192.453% |
| BioInvent International AB (publ) | 71.46 Million SEK | 99.783% |
| Alzinova AB (publ) | 270 Thousand SEK | 42.593% |
| Oncopeptides AB (publ) | 35.22 Million SEK | 99.56% |
| Pila Pharma AB (publ) | 1.46 Million SEK | 89.405% |
| Guard Therapeutics International AB (publ) | - SEK | -Infinity% |
| Scandinavian ChemoTech AB (publ) | 2.82 Million SEK | 94.507% |
| Simris Alg AB (publ) | 4.35 Million SEK | 96.44% |
| Diamyd Medical AB (publ) | 130 Thousand SEK | -19.231% |
| Xbrane Biopharma AB (publ) | 238.72 Million SEK | 99.935% |
| Ascelia Pharma AB (publ) | - SEK | -Infinity% |
| Diagonal Bio AB (publ) | 23 Thousand SEK | -573.913% |